Status:
COMPLETED
Treatment With AX200 for Acute Ischemic Stroke
Lead Sponsor:
Axaron Bioscience AG
Conditions:
Cerebral Stroke
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The AXIS study is a randomized, double-blind, placebo-controlled, dose-escalating phase IIa trial to investigate treatment with AX200 (granulocyte-colony stimulating factor; G-CSF) for acute ischemic ...
Eligibility Criteria
Inclusion
- Stroke onset within 12 hours prior to start of study agent administration
- Ischemic stroke in the middle cerebral artery (MCA) territory confirmed by magnetic resonance imaging (MRI)
Exclusion
- Time interval since stroke onset impossible to determine
- Carotid T-occlusion (magnetic resonance angiography \[MRA\])
- Subarachnoid hemorrhages
- Several safety parameters
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00132470
Start Date
December 1 2004
End Date
March 1 2007
Last Update
July 25 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurology University of Heidelberg
Heidelberg, Germany, 69120
2
Neurology University of Muenster
Münster, Germany, 48149